PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 141 participants.
Also called NCT04543812
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 141 participants
- Sponsor
- Registry
-
NCT04543812
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Taiwan
- Registry status
- Completed
Technical summary
Registry record NCT04543812. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-14 (actual); primary completion 2022-10-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD
- Condition
- Anemia of Chronic Kidney Disease
- Intervention (Drug)
- Ferric citrate
- Intervention (Drug)
- Placebo
- Lead sponsor
- Panion & BF Biotech Inc.
Record details
- Record id
cardio:ct-nct04543812- Content hash
ced958c13362f04046f9d278ddd65532eb9d91dd9a63d26ba05fea4965a5daf3